Blog

New research released last week suggests that sex matters when it comes to surgery. Researchers examined the sex of the surgeon and the sex of the patient in over a million surgeries and found that female patients with male doctors fared slightly worse than any other combination. The reason for the disparity likely comes down to communication and relationship-building.

Evidence has been accumulating steadily for over a decade that arthroscopic knee surgery to shave torn, degenerative cartilage does not help more than physical therapy.

Cartilage repair has an unwritten age limit. Around 55, most surgeons stop offering regenerative options and start talking about managing symptoms instead. The assumption is that older cartilage cells will not do the job.

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived m...

Current strategies for articular cartilage repair are largely focused on the treatment of localized cartilage defects, aiming to relieve symptoms and delay the progression of osteoarthritis.

Knee pain can make simple activities like walking, climbing stairs or playing with your kids feel impossible. If you have a cartilage injury, it likely won’t heal on its own and may worsen over time.

ntional neuroradiologist Marcel Maya, MD, co-chair of the Department of Imaging at Cedars-Sinai, made the diagnosis of an aneurysmal bone cyst, a rare, blood-filled tumor that can grow rapidly and, as in Soliz’s case, destabilize the spinal column and compress the spinal cord.

Angiosarcoma is a rare malignant neoplasm of endothelial cell origin, accounting for approximately 1–2% of all soft tissue sarcomas

Osteosarcoma remains a major therapeutic challenge in the metastatic, recurrent, or refractory setting

Researchers at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center are zeroing in on less toxic and more targeted strategies to combat Ewing sarcoma, an aggressive and rare pediatric cancer that develops in the bones and soft tissues.

A novel tetravalent DR5 agonist could become the first standard of care for conventional chondrosarcoma.